fbpx
    • Myeloma Crowd Newsroom
    • Jul 11, 2014

    Cure Magazine Features Chemo Brain Doc Notes smartphone app

June 15, 2014

Cure Magazine features the Chemo Brain Doc Notes app created by myeloma patient and Myeloma Crowd founder Jenny Ahlstrom in their June 2014 issue. Chemo Brain Doc Notes is a free iOS and Android app that helps patients remember the important questions for their next visit. For more about Chemo Brain Doc Notes, read more here.

Read the Cure Magazine article here.

 

About Author

Jenny A

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical trials. Founder of Myeloma Crowd, Myeloma Crowd Radio and the CrowdCare Foundation.

MYELOMA CROWD RESEARCH INITIATIVE
$118683 of $500,000 Raised
BRINGING THE RIGHT TREATMENT TO THE PATIENT AT THE RIGHT TIME
Please Help Us Reach Our Goal

AmazonSmile
More Articles
myeloma coach

Life With Multiple Myeloma Multiple Myeloma News

Introducing the New Myeloma Coach Program: Finding and Giving One-On-One Help

Mar 18, 2019

  You have cancer.  No one ever expects to hear those words.  Other people get cancer, not you.  Multiple Myeloma?  What in the world is that?  Most individuals diagnosed with myeloma have never heard of it before they were diagnosed.  But once diagnosed, they are immediately  flooded with information, questions, and options for treatment.  They […]

Multiple Myeloma News

Abbvie Halts New Patient Recruitment for Venetoclax Trials in Multiple Myeloma

Mar 19, 2019

AbbVie announced that the FDA has placed a partial clinical hold on all clinical trials using venetoclax in multiple myeloma. The hold was placed based on data from the Phase 3 BELLINI trial (a study for relapsed/refractory myeloma) in which a higher proportion of deaths were observed in the venetoclax arm compared to the control […]

CLR 131

Myeloma Clinical Trials

Clinical Trial: Overall Survival Lengthened for Relapsed/Refractory Myeloma Patients Using CLR 131 Cancer-Targeted Therapy

Feb 02, 2019

Myeloma patients who had relapsed after receiving both a proteasome inhibitor (like Velcade) and immunomodulator (like Revlimid) participated in a Phase I study of a new drug called CLR 131 and experienced an average 22 month overall survival.   While no head-to-head treatment comparisons have been performed, a 2016 article in the journal Bone Marrow Transplantation showed that […]

Get Started Today.

Find a Clinical Trial that's Right for You

Go

Thanks to our site sponsors: